This module is CPD certified, offering a certificate upon completion.
You will need to be signed in to MSD Connect to download the certificate.
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
This series of bite sized peer-to-peer videos by experienced clinical nurse specialists, specialist registrars and oncologists has been created to share their knowledge and experience of the day-to-day management of patients with mNSCLC treated with KEYTRUDA® (pembrolizumab) plus chemotherapy.
This module is part of a series of modules looking to share HCPs’ experiences across a range of topics. In this module we’ll start with how patients go into combination treatment and explore the proposed mode of action for KEYTRUDA. We’ll then look at the types of immune related adverse events which patients on KEYTRUDA plus chemotherapy may experience and how they may be managed. Finally, we’ll hear from a nurse about supporting patients as they complete their treatment and transition off KEYTRUDA.
This module is CPD certified, offering a certificate upon completion.
You will need to be signed in to MSD Connect to download the certificate.
Length: 00:59 | This video is best viewed in full screen, using the button in the bottom right
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 08:46 | This video is best viewed in full screen, using the button in the bottom right
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 08:31 | This video is best viewed in full screen, using the button in the bottom right
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 03:42 | This video is best viewed in full screen, using the button in the bottom right
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 09:53 | This video is best viewed in full screen, using the button in the bottom right
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 07:20 | This video is best viewed in full screen, using the button in the bottom right
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 07:28 | This video is best viewed in full screen, using the button in the bottom right
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 06:45 | This video is best viewed in full screen, using the button in the bottom right
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 01:04 | This video is best viewed in full screen, using the button in the bottom right
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
Loading profile
This section of the website contains promotional information intended for UK Healthcare Professionals only. If you are not a UK healthcare professional, please click here. GB‑NON‑07725 | Date of Preparation: August 2023
For information regarding KEYTRUDA® (pembrolizumab), please click on the relevant button below for information tailored to your needs.
Reporting side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects, you can help provide more information on the safety of this medicine.
Great Britain:
Summary of Product Characteristics | Patient Information Leaflet
Northern Ireland:
Summary of Product Characteristics | Patient Information Leaflet
To contact us please telephone 0208 154 8000 or email medicalinformationuk@msd.com
GB-PDO-02344 | Date of Preparation: August 2022
Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 233687 Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000)